Pricing & Reimbursement
A stable pricing and reimbursement framework with a horizon of four years would ensure predictability in the domestic and European markets. Greece as a pricing reference country would thus cease to be a source of volatility and surprises, and economic advantages would be gained by all stakeholders.
|The fiscal policies implemented so far to curb pharmaceutical expenditure have exclusively focused on pharmaceutical prices reduction measures, making these prices the lowest in Europe and unsustainable for pharmaceutical companies, thereby causing market distortions and supply shortages and hampering the access of patients to crucial treatments.εμπλεκόμενους|
- We call for a simpler and fairer pricing and reimbursement system, as the current system has outlived its usefulness. In this context, we advocate the need for a study to be prepared by a qualified expert team, with a view to developing a new pricing and reimbursement framework as those in place in other countries sharing common features with Greece. However, until the completion of such study, SFEE’s firm position is that all originator products (on- and off-patent) should be priced at the average of the three lowest prices in the European Union countries, and special care should be taken for cheap established medicines to ensure that they remain in the market.
- SFEE believes that innovation assessment is an important health policy tool, as it can provide a cost-benefit analysis of innovative medicines and demonstrate their added value, improve the quality of life of patients and help to rationalize the Greek health system.
- SFEE recommends the prompt establishment of a Health Technology Assessment (HTA) body to review reimbursement.
- Activation of a Negotiation Committee and use of uncertainty management policies, such as price-volume agreements, performance-based agreements on the basis of actual data obtainable from patient registries, and use of budget impact models (BIMs) by EOPYY for all new medicines.
- At the same time, SFEE supports the introduction of incentives for increasing the use of generics in order to save considerable resources that will enable innovative treatments to become available in the market and patients to have quick access to new medicines. Some of our proposals refer to the following:
- provision of effective incentives to all parties involved, i.e. patients, doctors and pharmacists;
- a stronger policy for promoting the use and public awareness of generics;
- implementation of control measures to prevent a shift from cheaper treatments (generic and off-patent) to more expensive treatments;
- Uncoupling pricing from reimbursement in order to establish a simpler pricing system that will not affect the prices of other countries (IRP) and, at the same time, a reimbursement system that focuses on the social security price as a measure of cost-saving (dual pricing).